2016 Blogging Report Technical Review 
Xconomy
JANUARY 3, 2018
One of the largest and most consequential data breaches in 2017 afflicted credit reporting agency Equifax, and it was hardly the only victim. The drumbeat of mishaps and scandals this year also included charges of sexual harassment and gender discrimination among tech companies and investors. Have all these.
Xconomy
NOVEMBER 13, 2016
View the Slideshow A little more than a year ago, amid a resurgence in San Diego’s software sector, Xconomy identified a baker’s dozen of local tech companies to watch in 2016. I met with Seed San Diego partners Taner Halicioglu and Eric Gasser, who also reviewed the companies and provided their feedback.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
SEPTEMBER 23, 2016
Just by calling her number in Louisiana from my couch in the Bay Area, I’ll hear hilarious commentary on the Clinton-Trump exchange from Eileen, a terrific reporter who’s wittier than most standup comics. I found another name for this low-tech form of long distance TV show sharing in the New York Times: “sync-watching.”
Xconomy
OCTOBER 7, 2016
military’s high-tech think tank DARPA described Safe Genes, a new program to fund safety measures that can be built into genome editing technology or counter its potential wayward effects. —The 2016 Nobel Prize for Physiology or Medicine went to Yoshinori Ohsumi of the Tokyo Institute of Technology. .
Xconomy
AUGUST 19, 2016
The CRISPR news this week doesn’t need a metaphor; the drama that MIT Technology Review reported can stand alone. — MIT Technology Review reported this week that a graduate student in the lab of Feng Zhang, Broad Institute gene-editing star, had accused the Broad of misleading the U.S. .
Xconomy
AUGUST 12, 2016
government’s Precision Medicine Initiative is an ambitious effort to collect the genomic data of 1 million Americans, and tech giant Alphabet (NASDAQ: GOOG ) is deeply involved. . —The U.S. Alex Lash examined the company’s role, via its biotech subsidiary Verily Life Sciences, in the massive project. —David H.
Xconomy
JUNE 17, 2016
The filing held some surprises , however, as Xconomy reported: plans to convert about $200 million in debt—a massive amount for a privately held biotech—into shares at the IPO, with some of those shares holding special privileges for their owners. . —Ben Fidler contributed to this report. Reprints | Share:
Expert insights. Personalized for you.
71 
Let's personalize your content